This study is being conducted to provide updated clinical data on safety and performance (demonstrated previously for CE marking under the Medical Devices Directive) Cooper Aqueous Eosin 2%. This is an observational study conducted under real-life conditions and as part of post-marketing surveillance activity for a device that has been on the market for a long time and a well-established technology, in accordance with the Medical Devices Regulations 2017 /745 (MDR) and MDCG 2020-6 guidelines. The study will be a multicenter, national, observational, prospective study, with a 7-day follow-up (+/- 2 day). 60 patients are scheduled.
Study Type
OBSERVATIONAL
Enrollment
67
Multiple locations
Multiple Locations, France
Percentage of patients with an SSDDS score < 3/6 or an improvement of at least 2 points
The SSDDS (Scoring System for Diaper Dermatitis Scale) score is a severity score : the sum of the scores for four areas: severity of erythema and irritation (score from 0 to 3), extension (0 to 1), presence of papules or pustules (0 to 1) and open skin (0 to 1). The possible scores range from 0 (fair skin) to 6 (extensive diaper rash including intense erythema, papules or pustules and open skin with lesion of the dermis).
Time frame: at day 7 +-2 days
Percentage of patients completely cured
Time frame: at day 7 +/-2 days
Healing time according to parent
Time frame: up to 9 days
Change of the SSDDS score between day 0 and day 7
The SSDDS (Scoring System for Diaper Dermatitis Scale) score is a severity score : the sum of the scores for four areas: severity of erythema and irritation (score from 0 to 3), extension (0 to 1), presence of papules or pustules (0 to 1) and open skin (0 to 1). The possible scores range from 0 (fair skin) to 6 (extensive diaper rash including intense erythema, papules or pustules and open skin with lesion of the dermis).
Time frame: at day 7 +/-2 days
Change in associated signs between day 0 and day 7
Time frame: at day 7 +/-2 days
Assessment of tolerance
Tolerance is measured by adverse events reported
Time frame: at day 7 +/-2 days
Assessment of compliance
According to the judgment of the investigator
Time frame: at day 7 +/-2 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.